Back to top
more

Enovis (ENOV)

(Real Time Quote from BATS)

$25.89 USD

25.89
372,947

-0.57 (-2.15%)

Updated Aug 6, 2025 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

UnitedHealth (UNH) Unveils its Latest Outlook: Key Takeaways

by Zacks Equity Research

UnitedHealth (UNH) expects the top line to be within the range of $400-$403 billion in 2024.

Zacks Equity Research

Here's Why Investors Should Hold Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna (CI) expects total medical customer growth to be a minimum of 1.4 million this year.

Zacks Equity Research

Tenet (THC) to Divest 3 Hospitals to Novant to Reduce Debt

by Zacks Equity Research

Tenet (THC) expects the divestment of the three South Carolina hospitals to fetch around $2.4 billion in cash.

Zacks Equity Research

Encompass Health (EHC) Opens Second Hospital in Wisconsin

by Zacks Equity Research

The inpatient rehabilitation hospital's opening in Fitchburg, WI, was moved up from the initially scheduled first quarter of 2024.

Zacks Equity Research

HCA Healthcare (HCA) Unveils Ambitious 5-Year Growth Targets

by Zacks Equity Research

Over the five-year horizon, HCA Healthcare (HCA) anticipates substantial 8-12% annual growth in earnings per share.

Zacks Equity Research

Can Enovis (ENOV) Climb 43.82% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Enovis (ENOV) points to a 43.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Brookdale Senior (BKD) Shares Rise 1.9% Despite Q3 Earnings Miss

by Zacks Equity Research

Brookdale Senior (BKD) expects adjusted EBITDA to be within the $77-$82 million range in the fourth quarter.

Zacks Equity Research

Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 5.66% and 0.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Enovis (ENOV) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Enovis (ENOV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Brian Bolan headshot

Bear Of The Day: Enovis (ENOV)

by Brian Bolan

Despite a good history of beating the number, estimates are sliding for this Medical Information Systems provider

Zacks Equity Research

Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 15.09% and 2.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 18.92% and 4.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Community Health Systems (CYH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Community Health Systems (CYH) delivered earnings and revenue surprises of -95.46% and 3.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enovis (ENOV) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 25.53% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Enovis (ENOV) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Enovis (ENOV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Enovis (ENOV) Q2 Earnings Beat Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 20.41% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.44% and 1.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ENOV vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ENOV vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Enovis (ENOV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 8.82% and 177.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for May 5th

by Zacks Equity Research

ENOV, FFIV, and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on May 5, 2022

Zacks Equity Research

Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.